SubjectWell

Ivor Clarke is the founder and Chief Executive Officer. As a venture-backed operating company, strategic decisions — including capital allocation and M&A — are approved by the board of directors, which includes representation from investors Chicago Pacific Founders and Windham Venture Partners.

SubjectWell combines de-identified insurance claims and electronic health record data covering approximately 120 million Americans. Algorithms match patient profiles against trial inclusion and exclusion criteria for active studies. Patients are then reached through targeted multi-channel outreach and can review trial information before consenting to be connected with a site.

SubjectWell is a venture-backed technology company, not a family office. It has raised capital from institutional investors including Chicago Pacific Founders, Windham Venture Partners, and Healthy Ventures. The firm generates revenue by charging pharmaceutical sponsors and contract research organizations for patient recruitment services.

SubjectWell recruits patients across more than 50 disease areas. The firm has significant depth in cardiology, gastroenterology, CNS disorders, and rare diseases. Its June 2024 acquisition of Oligo Medic added rheumatology as a specific area of operational strength.

SubjectWell does not conduct clinical trials. It functions as a patient recruitment and engagement layer that pre-screens and connects potential participants with investigator sites and sponsor-led trials. The firm's double-opt-in marketplace means patients consent both to learn about a trial and to have their information shared with the relevant site.